tbuckley/cabot-search huggingface dataset:
OS-009 Tumor size-dependent endothelial switch modulates CD8+ T cell immune surveillance in liver cancer
Authors: Carlotta Tacconi, Bianca Partini, Pietro Delfino, Chiara Laura, Gioia Ambrosi, Giulia Nosetto, Xenia Ficht, Davide Marotta, Cristian Beccaria, Monica Giannotta, Elisa Bono, Leonardo Giustini, Jose Garcia Manteiga, Micol Rava, Tamara Canu, Paolo Marra, Riccardo Leone, Tommaso Russo, Laura Perani, Federica Pedica, Andrea Raimondi, Nadia Santo, Antonio Esposito, Miriam Merad, Alessio Cantore, Luigi Naldini, Luca Guidotti, Donato Inverso, Federica Moalli, Matteo Iannacone
Journal: Journal of Hepatology (2025)
THU-224-YI Hepatocellular carcinoma risk scores and incidence during and after hepatitis C therapy with direct antiviral agents - data from the german hepatitis C-registry (DHC-R)
Authors: Magdalena Hahn, Peter Buggisch, Hartwig Klinker, Stefan Mauss, Uwe Naumann, Renate Heyne, Lutz Thomas, Yvonne Serfert, Heinz Hartmann, Stefan Zeuzem, Kristin Berry, Heiner Wedemeyer, George Ioannou, Thomas Berg
Journal: Journal of Hepatology (2025)
SAT-140 Predictive value of systemic inflammation biomarkers towards recompensation versus progression to further decompensation in patients with decompensated cirrhosis
Authors: Dalila Costa, Benedikt Hofer, Georg Kramer, Ana Frias, Ricardo Silvestre, Joana Camões Neves, João Belmiro, Kerstin Zinober, Vlad Taru, Georg Semmler, Benedikt Simbrunner, Carla Rolanda, Mattias Mandorfer, Thomas Reiberger
Journal: Journal of Hepatology (2025)
THU-492-YI Altered high density lipoprotein 3 and associated proteins signatures contribute to immune dysfunction in alcohol associated liver cirrhosis
Authors: Shivani Gautam, Sukriti Baweja, Vibhuti Jakhmola, Harshvardhan Tevethia, Guresh Kumar, Amar Mukund, Shiv Kumar Sarin
Journal: Journal of Hepatology (2025)
SAT-209 Randomized, open-label, phase 2a comparator study to assess the pharmacodynamics, safety and pharmacokinetics of oral administration of mnk6106 (l-ornithine phenylacetate) vs. rifaximin in subjects with hepatic cirrhosis and a previous history of hepatic encephalopathy
Authors: Darren Rubin, Tarek Hassanein, Peter Winkle, Eric J. Lawitz, Roxanna Stoici, Zeid Kayali, Grisell Ortiz Lasanta, Rajiv Jalan
Journal: Journal of Hepatology (2025)
THU-165-YI Spleen Area affects the predictive performance of the platelet count-based non-invasive tools in MASLD
Authors: Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Annachiara Coppola, Simone Olivieri, Luigi Vitale, Marco Niosi, Alessandro Federico
Journal: Journal of Hepatology (2025)
WED-397 Nuclear magnetic resonance metabolomics for non-invasive MASLD phenotyping
Authors: Vlad Ratziu, Anja Svenson, Jan-Peter Sowa, Eric Schiffer, John Venz, Eric Schiffer, Christian Karger, Tiziana Errera, Ali Canbay, Bárbara Luna, Luis Téllez, Jesus Donate, Sonia Camano, Andreas Geier
Journal: Journal of Hepatology (2025)
TOP-379-YI Untargeted lipidomic profiling in pediatric metabolic dysfunction-associated steatohepatitis: insights from youth enrolled in NASH CRN studies
Authors: Gahyun Lim, Helaina Huneault, Chih-Yu Chen, Grey Won, Cristian Sanchez-Torres, Kristal Maner-Smith, Miriam Vos
Journal: Journal of Hepatology (2025)
WED-337 Matrix metalloproteinase-7 and osteopontin secretion are specifically upregulated in a novel human precision-cut liver slices model of biliary atresia-associated liver fibrosis
Authors: Jeske Fridrichs, Mark Nomden, Sarah Mitchel, Jeffrey Sewdihal, Alan Gorter, Dorenda Oosterhui, Marius van den Heuvel, Henkjan J. Verkade, Vincent de Meijer, JBF Hulscher, Peter Olinga
Journal: Journal of Hepatology (2025)
FRI-077-YI T-cell receptor analysis of circulating T cells reveals non-epitope- driven clonal expansion in metabolic-associated steatotic liver disease
Authors: Xinlei Zhao, Sven Aschenbroich, Xiaojie Yu, Su Ir Lyu, Ulrike Koitzsch, Nadja Sereda, Karl-Peter Rheinwalt, Andreas Plamper, Nan Fang, Robert Schierwagen, Jonel Trebicka, Uta Drebber, Margarete Odenthal, Maximilian Joseph Brol
Journal: Journal of Hepatology (2025)
SAT-124-YI Harnessing human immune system mouse models to validate NADPH oxidase 1 inhibition as a treatment for hepatocellular carcinoma
Authors: Zenzi de Vos, Lander Heyerick, Hannah Stocks, Andy Wullaert, Anne Hoorens, Sander Lefere, Sarah Raevens, Anja Geerts, Xavier Verhelst, Hans van Vlierberghe, Lindsey Devisscher
Journal: Journal of Hepatology (2025)
SAT-381 Rapid liver disease progression after first hepatic decompensation in individuals with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)
Authors: Lorenz Balcar, Malin Fromme, Naomi Kappe, Benedikt Schaefer, Sonèa Franèková, Jan Sperl, Natalie Van den Ende, Jan Stolk, Mathias Jachs, Georg Semmler, Benedikt Hofer, Tammo Lambert Tergast, Hannah Schneider, Martin Wagner, Monica Pons, Harald Hofer, Markus Peck-Radosavljevic, Thomas Reiberger, Michael Trauner, Benjamin Maasoumy, Heinz Zoller, Jef Verbeek, Bart van Hoek, Pavel Strnad, Mattias Mandorfer
Journal: Journal of Hepatology (2025)
OS-068 Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients fromthe D-Solve consortium and HDV1000 database
Authors: Habiba Kamal, Monica Radu, Dana Sambarino, Anika Wranke, Ivana Carey, Miroslava Subic-Levrero, Karin Lindahl, Lisa Sandmann, Petra Dörge, Julia Kahlhöfer, Fabien Zoulim, Kosh Agarwal, Heiner Wedemeyer, Pietro Lampertico, Florin Alexandru Caruntu, Soo Aleman, Elisabetta Degasperi
Journal: Journal of Hepatology (2025)
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification
Authors: Franziska Beck, Lina Jegodzinski, Hans Benno Leicht, Florian P. Reiter, Friedhelm Sayk, Ina Bergheim, Jens U. Marquardt, Andreas Geier, Monika Rau
Journal: Journal of Hepatology (2025)
WED-376 Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602 K during a phase IIb clinical trial
Authors: Alejandro Mayorca Guiliani, Peder Frederiksen, Morten Karsdal, Jerry Colca, Diana Julie Leeming
Journal: Journal of Hepatology (2025)
FRI-372 MASH-in-a-dish: a multicellular pre-clinical model to identify targetable metabolite crosstalk in MASH
Authors: Jung-Chin Chang, Annika Sullock Enzlin, Saskia van Essen, Rachel Thomas, Laura Bongiovanni, Thomas Kluiver, Weng Chuan Peng, Esther Zaal, Bart Westendorp, Alain de Bruin, Bernd Helms, Celia Berkers
Journal: Journal of Hepatology (2025)
LBP-030-YI Pitfalls in creatinine measurement and their impact on model for end stage liver disease score
Authors: Eda Kaya, Christin Quast, Maria Stepanova, Jasmin Weninger, Oliver Goetze, Abdurrahman Coskun, Martina Broecker-Preuss, Zobair Younossi, Jan-Peter Sowa, Mustafa Özcürümez, Ali Canbay
Journal: Journal of Hepatology (2025)
SAT-216 The most common bacterial isolates in spontaneous bacterial peritonitis in a tertiary hospital center in Croatia and their antibiotic resistance
Authors: Sanja Stojsavljevic Shapeski, Lucija Virovicè Jukić, Mario Živković, Jelena Lucin, Branka Ðuras Cuculić, Neven Ljubicèić, Neven Baršić, Alen Bišcanin, Tajana Pavić, Ivan Lerotić, Vedran Tomašić, Ivan Budimir, Davor Hrabar, Marija Pericè Bešlić
Journal: Journal of Hepatology (2025)
THU-389 The severityof MASLD is associated with chronic kidney disease in patients with type 2 diabetes and/or obesity
Authors: Bérénice Ségrestin, Bruno Vergeès, Mallaury Cardoso, Dominique Delaunay, Rouland Alexia, Hadjadj Samy, Primot Claire, Pierre Morcel, Jean-Michel Petit, Sybil Charrieère, Philippe Moulin, Laetitia Koppe, Emmanuel Disse, Bertrand Cariou, Cyrielle Caussy
Journal: Journal of Hepatology (2025)
THU-140 The in vitro immune response of mononuclear cells to Escherichia coli is not dependent on antibiotic multidrug resistance
Authors: Berta Cuyàs, Elisabet Cantó, Elisabet Sanchez, Elisenda Miró, Edilmar Alvarado-Tapias, Eva Roman, Maria Poca, Ferran Navarro, Àngels Escorsell, Silvia Vidal, German Soriano
Journal: Journal of Hepatology (2025)
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study
Authors: Markus Maagaard, Nikolaj Torp, Cecilie Løbel, Katrine Bech, Helle Schnefeld, Georg Semmler, Katrine Lindvig, Katrine Thorhauge, Stine Johansen, Johanne Kragh Hansen, Camilla Dalby Hansen, Ida Falk Villesen, Peter Andersen, Mark Haastrup, Niels Foged, Maja Thiele, Mads Israelsen, Aleksander Krag
Journal: Journal of Hepatology (2025)
WED-306 The kinetic of HBsAg isoforms predicts response to BLV and pegylated interferon alfa2a in patients with chronic hepatitis delta
Authors: Maria Pfefferkorn, Heinrich Rodemerk, Elisabetta Degasperi, Jonathan Seltmann, Luise Drechsel, Sara Sopena Santisteve, Madlen Matz-Soja, Dieter Glebe, Maria Buti, Heyne Renate, Patrick Ingiliz, Maurizia Brunetto, Thomas Berg, Pietro Lampertico, Florian van Bömmel
Journal: Journal of Hepatology (2025)
SAT-425 Evaluating the efficacy of a carnitine orotate and biphenyl dimethyl dicarboxylate complex in the pathogenetic treatment of metabolic-associated fatty liver disease: midterm data
Authors: Aliya Kaisina, Almagul Jumabayeva, Jamilya Kaibullayeva, Balzhan Nugmanova, Aliya Balabek, Aizhan Muratbekova, Assya Yergaliyeva, Tamilya Reshidova
Journal: Journal of Hepatology (2025)
OS-080-YI Multimodal single-nuclei atlas of MASLD progression uncovers a link to type 2 diabetes
Authors: Laura Pikkupera, Rikard Fred, Malte Thodberg, Thomas Koefoed, Benedicte Schultz Kapel, Shanshan He, Kata Krizic, Mikkel Werge, Sofie Boesgaard Neestrup Hansen, Cesar Medina, Elisabeth Galsgaard, Lise Lotte Gluud, Torben Hansen
Journal: Journal of Hepatology (2025)
WED-492 Liver fibrosis is a strong predictor of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease independent from metabolic syndrome
Authors: WeiWei Xu, Guyu Zeng, Peizhi Wang, Qinxue Li, Tianyu Li, Yue Tian, Bochuan Huang, Jinqing Yuan, Diederick Grobbee, Manuel Castro Cabezas
Journal: Journal of Hepatology (2025)
THU-100 Functional properties of unannotated, small RNA clusters during hepatocarcinogenesis
Authors: Francesca Pagani, Franziska Giehren, Juliane Diederichs, Ramsha Masood, Joao Gorgulho, Bojan Losic, Augusto Villanueva, Henning Wege, Ansgar W. Lohse, Samuel Huber, Guido Sauter, Asmus Heumann, Tarik Ghadban, Thilo Hackert, Mattia Bugatti, William Vermi, Kornelius Schulze, Johann von Felden
Journal: Journal of Hepatology (2025)
LBO-003 Efficacy and safety of long-term human albumin therapy in cirrhotic patients with acute decompensation and ascites: topline results of the PRECIOSA trial
Authors: Jacqueline G. O’Leary, Giovanni Perricone, Wim Laleman, Tamara Milovanovic, Mireia Torres, Neus Campins, Peter Nelson, Paolo Angeli, Tarek Hassanein, Javier Fernandez
Journal: Journal of Hepatology (2025)
SAT-468 Hot &amp; cold fibrosis: fibro-inflammatory biomarkers as prognostic tools in alcohol-related liver disease
Authors: Andressa de Zawadzki, Maja Thiele, Stine Johansen, Peter Andersen, Ida Falk Villesen, Morten Karsdal, Diana Julie Leeming, Aleksander Krag
Journal: Journal of Hepatology (2025)
THU-450 Cryptogenic cirrhosis in Brazil: much beyond burned-out metabolic associated steatohepatitis
Authors: Paulo Bittencourt, Elodie Hyppolito, Ludmila Guedes, Natalia Trevizoli, Débora Terrabuio, Yasmin Amorim, Marina Queiroz, Jose Telmo Valenca Valenca, José Huygens Parente Garcia, Francisco Guilherme Cancela Penna, Daniel Terra, Henrique Rocha, Priscila Campos, Marcus Gomes, Matheus Aires, Liana Codes, Clebia de Lima, Paula Vidigal, Andre Watanabe, Luiz C. D’Albuquerque
Journal: Journal of Hepatology (2025)
THU-239 Long-term prognosis and changes in liver function after direct- acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus
Authors: Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Akio Ido, Hidekatsu Kuroda, Daiki Miki, Masayuki Kurosaki, Yoichi Hiasa, Norifumi Kawada, Taro Yamashita, Goki Suda, Hiroshi Yatsuhashi, Hitoshi Yoshiji, Naoya Kato, Taro Takami, Hisamitsu Miyaaki, Kentaro Matsuura, Yasuhiro Asahina, Yoshito Itoh, Ryosuke Tateishi, Yasunari Nakamoto, Eiji Kakazu, Shuji Terai, Masahito Shimizu, Yoshiyuki Ueno, Norio Akuta, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Journal: Journal of Hepatology (2025)
THU-253 IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance
Authors: Christine L. Espiritu, Timothy Eley, Kevin Gray, Mark Anderson, Tiffany Fortney, Gavin Cloherty, Elina Medvedeva, Man-Fung Yuen, Jeong Heo, Ronald G. Nahass, Grace Lai-Hung Wong, Tatiana Burda, Kalyan Bhamidimarri, Tsung-Hui Hu, Tuan T. Nguyen, Young-Suk Lim, Chi-Yi Chen, Stuart C. Gordon, Jacinta Holmes, Wan-Long Chuang, Anita Kohli, Naim Alkhouri, Angela M. Lam, Michael J. Sofia, Karen D. Sims, Emily P. Thi
Journal: Journal of Hepatology (2025)
Comparative phylogenetics reveal clade-specific drivers of recombination rate evolution across vertebrates
Authors: Taylor Szasz-Green, Katherynne Shores, Vineel Vanga, Luke Zacharias, Andrew K Lawton, Amy L Dapper
Journal: Molecular Biology and Evolution (2025)

Abstract Meiotic recombination is an integral cellular process, required for the production of viable gametes. Recombination rate is a fundamental genomic parameter, modulating genomic responses to selection. Our increasingly detailed understanding of its molecular underpinnings raises the prospect that we can gain insight into trait divergence by examining the molecular evolution of recombination genes from a pathway perspective, as in mammals, where protein-coding changes in later stages of the recombination pathway are connected to divergence in intra-clade recombination rate. Here, we leverage increased availability of avian and teleost genomes to reconstruct the evolution of the recombination pathway across two additional vertebrate clades: birds, which have higher and more variable rates of recombination and similar divergence times to mammals, and teleost fish, which have much deeper divergence times. Rates of molecular evolution of recombination genes are highly correlated between vertebrate clades and significantly elevated compared to control panels, suggesting that they experience similar selective pressures. Avian recombination genes are significantly more likely to exhibit signatures of positive selection than other clades, unrestricted to later stages of the pathway. Signatures of positive selection in genes linked to recombination rate variation in mammalian populations and those with signatures of positive selection across the avian phylogeny are highly correlated. In contrast, teleost fish recombination genes have significantly less evidence of positive selection despite high intra-clade recombination rate variability. Gaining clade-specific understanding of patterns of variation in recombination genes can elucidate drivers of recombination rate and thus, factors influencing genetic diversity, selection efficacy, and species divergence.
Economic Inequality and Mental Health: Causality, Mechanisms, and Interventions
Authors: Divyangana Rakesh, Koichiro Shiba, Michèle Lamont, Crick Lund, Kate E. Pickett, Tyler J. VanderWeele, Vikram Patel
Journal: Annual Review of Clinical Psychology (2025)

Almost all countries in the world have witnessed a rapid increase in levels of economic inequality, a measure of the distribution of income and wealth across the population, since the advent of neoliberal economic policies in the 1970s. In this review, we conceptualize inequality as an ecological construct and discuss why it matters for the mental health of populations and for individual clinical outcomes. We then discuss some of the key mechanisms through which economic inequality influences mental health beyond poverty itself: social comparison and social capital. We also consider how the effect might vary across specific vulnerable groups in the population, such as young people and minoritized communities. Finally, we discuss methodological challenges in studying the relationship between inequality and mental health and conclude by outlining future research directions and possible interventions at the governmental, community, and individual levels to mitigate the negative mental health consequences of economic inequality.
Patient-derived models of <i>UBA5-</i> associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenues
Authors: Helen Chen, Christy W. LaFlamme, Yong-Dong Wang, Aidan W. Blan, Nikki Koehler, Renata Mendonca Moraes, Athena R. Olszewski, Edith P. Almanza Fuerte, Emily S. Bonkowski, Richa Bajpai, Alfonso Lavado, Shondra M. Pruett-Miller, Heather C. Mefford
Journal: Science Translational Medicine (2025)

UBA5 encodes for the E1 enzyme of the UFMylation cascade, which plays an essential role in endoplasmic reticulum (ER) homeostasis. The clinical phenotypes of UBA5 -associated encephalopathy include developmental delays, epilepsy, and intellectual disability. To date, there is no humanized neuronal model to study the cellular and molecular consequences of UBA5 pathogenic variants. We developed and characterized patient-derived cortical organoid cultures from two patients with compound heterozygous variants in UBA5 . Both shared the same missense variant, which encodes a hypomorphic allele (p.A371T), along with a nonsense variant (p.G267* or p.A123fs*4). Single-cell RNA sequencing of 100-day organoids identified defects in GABAergic interneuron development. We demonstrated aberrant neuronal firing and reduction in size of patient-derived organoids. Mechanistically, we showed that ER homeostasis is perturbed along with an exacerbated unfolded protein response pathway in engineered U87-MG cells and patient-derived organoids expressing UBA5 pathogenic variants. We also assessed two potential therapeutic modalities that augmented UBA5 protein abundance to rescue aberrant molecular and cellular phenotypes. We assessed SINEUP, a long noncoding RNA that augments translation efficiency, and CRISPRa, a modified CRISPR-Cas9 approach to augment transcription efficiency to increase UBA5 protein production. Our study provides a humanized model that allows further investigations of UBA5 variants in the brain and highlights promising approaches to alleviate cellular aberrations for this rare, developmental disorder.
PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry
Authors: Brendon E. Cook, Thomas C. Pickel, Sangram Nag, Philippe N. Bolduc, Rouaa Beshr, Anton Forsberg Morén, Cathy Muste, Giulia Boscutti, Di Jiang, Long Yuan, Prodip Datta, Piotr Ochniewicz, Yasir Khani Meynaq, Sac-Pham Tang, Christophe Plisson, Mario Amatruda, Qize Zhang, Jonathan M. DuBois, Armin Delavari, Stephanie K. Klein, Ildiko Polyak, Adebowale Shoroye, Sara Girmay, Christer Halldin, Laurent Martarello, Emily A. Peterson, Maciej Kaliszczak
Journal: Science Translational Medicine (2025)

Determination of a drug’s biodistribution is critical to ensure that it reaches the target tissue of interest. This is particularly challenging in the brain, where invasive sampling methods may not be possible. Here, we present a pretargeted positron emission tomography (PET) imaging methodology that uses bioorthogonal click chemistry to determine the distribution of an antisense oligonucleotide (ASO) in the brains of rats and nonhuman primates after intrathecal dosing of ASO. A PET tracer, [ 18 F]BIO-687, bearing a click-reactive trans -cyclooctene was developed and tested in conjunction with a test Malat1 ASO conjugated with a methyltetrazine group. PET imaging in rats demonstrated that the tracer had good kinetic properties for PET imaging in the rodent central nervous system and could react to form a covalent linkage with high specificity to the methyltetrazine-conjugated ASO in vivo. Furthermore, the amount of PET tracer reacted by cycloaddition with the methyltetrazine was determined to be dependent on the concentration of ASO-methyltetrazine in rat brain tissue, as determined by comparing the PET imaging signal with the liquid chromatography–mass spectrometry signal in the tissue homogenates. The approach was evaluated in cynomolgus macaques using both the Malat1 test ASO and a candidate therapeutic ASO, BIIB080, targeting the microtubule-associated protein tau ( MAPT ) gene. PET imaging showed favorable tracer kinetics and specific binding to both ASOs in nonhuman primate (NHP) brain in vivo. These results suggest that the PET imaging tracer [ 18 F]BIO-687 could show the distribution of intrathecally delivered ASOs in the rat and NHP brains.
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Authors: Christina Dold, Blanché Oguti, Laura Silva-Reyes, Anna Stanzelova, Meriel Raymond, Catherine C. Smith, Maria Moore, Anna Barton, Edward M. Choi, Emma Plested, Kiarash Tanha, Jennifer Louth, Ann Holland, Robert Cook, Jessica King, Jay Lucidarme, Ray Borrow, Adrian V. S. Hill, Peter T. Beernink, Xinxue Liu, Andrew J. Pollard, Christine S. Rollier
Journal: Science Translational Medicine (2025)

Capsular group B meningococcus (MenB) remains an important cause of disease globally, and additional vaccines against MenB would aid in reducing the incidence of infection. Previous work has demonstrated that a MenB adenoviral-vectored vaccine, ChAdOx1 MenB.1, elicited high serum bactericidal responses in preclinical models after a single dose, supporting further clinical development of this vaccine. Here, we report the results of a trial designed to assess the safety and immunogenicity of ChAdOx1 MenB.1 in healthy adults aged 18 to 50. In this phase 1/2a, single-center trial, participants received one or two doses of ChAdOx1 MenB.1 at days 0 and 180. One dose of ChAdOx1 MenB.1 was also given at day 180 to some individuals primed with one dose of 4CMenB at day 0. Participants recorded their symptoms in an electronic diary after vaccination, and safety blood readouts were monitored. Serum bactericidal antibody (SBA) assays were performed against a panel of MenB target strains. ChAdOx1 MenB.1 was well tolerated with no safety concerns and elicited protective SBA titers against a MenB strain expressing a homologous factor H–binding protein (fHbp) variant in 100% of participants after two doses. However, cross-reactivity analysis indicated a low SBA response to strains expressing heterologous fHbp, suggesting that a multivalent vaccine may be needed. In sum, ChAdOx1 MenB.1 is immunogenic in humans, and addition of another fHbp variant or of another antigen in this platform could provide an approach to extend protection against endemic MenB disease.